Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06235892

Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure

The goal of this clinical trial is that validation of the non-invasive biomarkers of the AGORA algorithm should make it possible to select patients with a very low immunological risk of graft failure to authorize safe minimization of their immunosuppression for adult patients at one-year post kidney transplantation.

The main question of the AGORAC trial is to demonstrate the impact of TACROLIMUS minimization using AGORA algorithm compared to standard of care on the kidney function 18 months after the minimization period.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Organ Grafts

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CHU de NANTES, Nantes, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • First kidney transplantation
  • Living or brain death or
  • Donation after circulatory death (Maastricht 3) donor,Compatible for ABO group with the donor,
  • cPRA (Panel Reactive Antibody Calculated ) (or TGI: Incompatible Graft Rate )<20% on the day of the transplantation and no DSA (MFI <500) at pre transplant and at the time of the inclusion at one-year post transplantation (between 350 and 515 days after the transplantation.
  • Eplet Mismatchs <= 14
  • Normal or IFTA 1-2 histology on one-year surveillance biopsy.
  • Patient insured under a health insurance scheme, according to national regulation.
  • Patient (of childbearing age) with effective contraception.
  • Patients treated with Tacrolimus (Prograf® or Advagraf®) and MMF / MPS (Mycophenolate Sodium) +/- Corticosteroid (CS)

Exclusion criteria

  • Donation after circulatory death maastricht 2 (uncontrolled) and maastricht 1
  • Pregnant women (serum or urine test), breastfeeding women
  • Patient under legal protection (incl. under guardianship or trusteeship)
  • Participation to a drug interventional study within 1 month prior to the inclusion
  • Any retransplantation and combined transplantations and also other organ previous transplantations
  • History of lymphoproliferative disorders
  • Diagnosis of a malignant disease (according to the type of malignancy)
  • Hepatitis C antibody or hepatitis B surface antigen (HbsAg) positive patient or HIV infection

Treatment and study plan

Tacrolimus

Drug

TACROLIMUS 2-3.5 ng/ml

Primary outcomes

  1. Improvement of the renal function at 18 months after "ultra" minimization of Tacrolimus

    Time frame: Month 18

    Improvement will be assessed by measured glomerular filtration rate (mGFR) iohexol clearance.

Secondary outcomes

  1. Incidence of biopsy-proven acute rejection (BPAR) according to the 2017 Banff classification (including borderline lesions)

    Time frame: Month 18

  2. Type, severity and treatment of biopsy-proven acute rejection ( BPAR)

    Time frame: Month 18

  3. Appearance of de novo donor-specific alloantibody (DSA) (4 digits and MFI treshold >500)

    Time frame: Month 18

  4. Appearance or worsening of histological lesions of interstitial fibrosis and inflammatory tubular atrophy (IFTA) of study biopsy by considering that only patients with normal histology or with an IFTA-1 or 2will be randomized

    Time frame: Month 18

  5. Prevalence of death, and graft loss (dialysis start or retransplantation) at end of study

    Time frame: Month 18

  6. Prevalence of metabolic disorders: post-transplant diabetes mellitus (PTDM), dyslipidaemia and hypertension at end of study

    Time frame: Month 18

  7. Treatment adherence consisting in monitoring immunosuppression adherence using Trackyourmed® to monitor individual variability tacrolimus intake

    Time frame: Month 18

  8. Change in quality of life estimated using the EQ-5D ( EuroQol instrument - dimensions) questionnaire fulfilled by patients at baseline, Month 3, Month 6, Month 9, Month 12, Month15 and Month18

    Time frame: Month 3, Month 6, Month 9, Month 12, Month15 and Month18

    There is two score in the EQ-5D-5L The first one is the descriptive system: Minimum value:5 ( no problems on any dimension) Maximum value: 25 ( extreme problems on all dimensions)

    The second score is EQ VAS (EuroQol vertical visual analogue scale) score. It is rated on a scale of 0-100 points. 0 points correspond to the worst possible health status, while 100 points correspond to the best possible health status.

Study contacts

Contact information is provided by the study sponsor or research team.

Magali GIRAL

CONTACT

[email protected]

+33240087443

Sonia Brinet

CONTACT

+33253526126

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

Prospective, Multicenter, Randomized, Open-label, Parallel-group Controlled Phase 3 Study of Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure

Acronym: AGORAC

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Feb 1, 2024
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.